Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2022-10-14 Asarina Pharma Asarina Pharma: Full rekrytering och sista patienten randomiserad i den viktiga studien om Tourettes syndrom Pressreleaser Ladda ner | Visa Stäng
2022-10-14 Asarina Pharma Asarina Pharma: Patient recruitment completed in landmark Tourette syndrome study Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Omfattande ny preklinisk studie ökar säkerheten av Asarina Pharmas resultat om en viktig stressmekanism involverad i Tourettes syndrom och OCD Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD Pressreleaser Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Q2 2022 Report released Rapporter Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Rapport för andra kvartalet 2022 släppt Rapporter Ladda ner | Visa Stäng
2022-06-23 Asarina Pharma Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 23 Jun 2022 | Asarina Pharma

Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen

On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the ”Loan Agreement”). ÖSS has now, in accordance with the Loan Agreement, requested that Asarina Pharma repay the outstanding loan amount plus accrued interest, corresponding to a total of SEK 5,884,296.35, with shares. Thus, the Company has, with support of the authorisation from the Annual General Meeting on 4 May 2022, resolved on a directed issue of shares to ÖSS (the ”Share Issue”). In accordance with the Loan Agreement, the subscription price per share is based on the volume-weighted average price for the Company’s share during a period of 10 trading days before the conversion date and amounts to SEK 1.51.

The Share Issue means that the number of shares in the Company increases by 3,896,885 and the share capital increases by SEK 974,221.29, entailing a dilution of 17.21 percent. After the Share Issue, the number of shares in Asarina Pharma will amount to 22,641,409 and the share capital will amount to SEK 5,660,352.48.

”The conversion of the ÖSS loan strengthens our financial position by removing the repayment obligation in June 2023 and allows us to focus on the phase IIa study in Tourette Syndrome. We are thankful for the support that we have received from Östersjöstiftelsen”, comments Peter Nordkild, CEO of Asarina Pharma.

The information was submitted for publication, through the agency of the contact persons set out above, at 11.15 CET on 23 June 2022.

2022-06-23 Asarina Pharma Asarina Pharma genomför en riktad nyemission av aktier efter begäran om lånkonvertering från Östersjöstiftelsen Pressreleaser Ladda ner | Visa Stäng
2022-05-25 Asarina Pharma Asarina Pharma AB (publ) Rapport för första kvartalet 2022 släppt Rapporter Ladda ner | Visa Stäng
2022-05-25 Asarina Pharma Asarina Pharma AB (publ) Q1 2022 Report released Rapporter Ladda ner | Visa Stäng
2022-05-04 Asarina Pharma Kommuniké från årsstämma i Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-05-04 Asarina Pharma Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-06 Asarina Pharma Asarina Pharma: ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED Pressreleaser Ladda ner | Visa Stäng
2022-04-06 Asarina Pharma Asarina Pharma: ASARINA PHARMA AB (publ) ÅRSREDOVISNING 2021 PUBLICERAD Pressreleaser Ladda ner | Visa Stäng
2022-04-05 Asarina Pharma Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-05 Asarina Pharma Asarina Pharma: KALLELSE TILL ÅRSSTÄMMA i ASARINA PHARMA AB (publ) Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

25 Feb 2023 | Kvartalsrapport 2022-Q3